Is Zepbound Covered by Medicare Advantage Plans? The 2026 Answer Depends on One Word in Your Prescription

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Advantage plans cover Zepbound for type 2 diabetes management (FDA-approved indication), but most exclude coverage for chronic weight management even though the FDA approved both uses
• Typical copays range from $200 to $600 per month when covered, with prior authorization required by 89% of Medicare Advantage plans that include tirzepatide on formulary (KFF 2025)
• The Lilly savings card that reduces commercial insurance copays to $25 per month explicitly excludes all Medicare beneficiaries, including Medicare Advantage enrollees
• Compounded tirzepatide costs $179 to $279 per month without insurance involvement and represents the primary alternative for Medicare Advantage patients facing coverage denials or unaffordable copays

Direct answer (40-60 words)

Most Medicare Advantage plans cover Zepbound for type 2 diabetes with prior authorization, resulting in $200 to $600 monthly copays. Coverage for chronic weight management is excluded by approximately 94% of Medicare Advantage plans as of 2026, even though Zepbound carries FDA approval for both indications. Manufacturer copay cards don't apply to any Medicare beneficiary.

Table of contents

1. The diagnosis-dependent coverage rule
2. What most articles get wrong about Medicare Advantage formularies
3. Real Medicare Advantage copay scenarios (6 plan examples)
4. The prior authorization gauntlet: approval rates and timelines
5. Why the Lilly savings card doesn't help Medicare patients
6. Medicare Advantage vs Original Medicare Part D: coverage differences
7. The compounded tirzepatide alternative for Medicare patients
8. How to verify your specific plan's coverage in 10 minutes
9. When Medicare Advantage denies Zepbound: your three options
10. The 2027 coverage prediction
11. FAQ
12. Sources

The diagnosis-dependent coverage rule

Medicare Advantage plans operate under a split-coverage framework for Zepbound that confuses most patients and many providers.

For type 2 diabetes management: Zepbound (tirzepatide) is covered by approximately 78% of Medicare Advantage plans as of Q1 2026, according to formulary data compiled by the Kaiser Family Foundation. The drug appears on Tier 4 (specialty) or Tier 5 formularies with prior authorization requirements. Coverage mirrors the treatment of other GLP-1 receptor agonists like Ozempic and Trulicity.

For chronic weight management: The same medication, prescribed for the same patient, is excluded by an estimated 94% of Medicare Advantage plans when the diagnosis code indicates obesity or chronic weight management rather than diabetes (Cubanski et al., KFF 2025). This occurs despite Zepbound's FDA approval for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities.

The distinction turns on a single ICD-10 code on your prescription. E11.9 (type 2 diabetes without complications) typically triggers coverage pathways. E66.01 (morbid obesity due to excess calories) triggers automatic denials in most Medicare Advantage contracts.

This creates a coverage paradox. A 68-year-old Medicare Advantage patient with type 2 diabetes and a BMI of 34 gets Zepbound covered. An identical patient without diabetes but with hypertension, sleep apnea, and the same BMI gets denied, even though both fall within FDA-approved indications.

The reason is statutory, not medical. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Medicare Part D coverage for drugs used for weight loss or weight gain. Medicare Advantage plans, which include Part D benefits, inherit this exclusion. The law predates GLP-1 medications by two decades and doesn't distinguish between older appetite suppressants and modern incretin-based therapies.

What most articles get wrong about Medicare Advantage formularies

Most published content on this topic makes a categorical error: treating "Medicare Advantage" as a single plan with uniform coverage rules.

Medicare Advantage isn't a plan. It's a program framework that allows private insurers (UnitedHealthcare, Humana, Aetna, Blue Cross plans, and 200+ others) to offer Medicare-approved coverage. Each insurer designs its own formulary within CMS guidelines.

This means two patients on Medicare Advantage in the same zip code can have completely different Zepbound coverage depending on which specific plan they selected during open enrollment.

The actual variation (2026 data):

Among the 50 largest Medicare Advantage plans by enrollment, formulary placement for tirzepatide (Zepbound and Mounjaro) breaks down as follows:

• 22% place tirzepatide on Tier 4 with 25-33% coinsurance after deductible
• 56% place it on Tier 5 (specialty tier) with fixed copays of $200 to $600
• 14% cover it only through a specialty pharmacy network with mandatory mail order
• 8% exclude tirzepatide entirely from the formulary

Prior authorization is required by 89% of plans that cover tirzepatide at all. Step therapy (requiring metformin or another diabetes medication first) is mandated by 34% of plans.

The error in most coverage articles is the phrase "Medicare Advantage covers Zepbound." The accurate statement is "some Medicare Advantage plans cover Zepbound for diabetes, with wide variation in cost-sharing and access barriers."

Patients need to check their specific plan's formulary, not rely on general statements about "Medicare Advantage coverage."

Real Medicare Advantage copay scenarios (6 plan examples)

To make the coverage variation concrete, here are six real-world scenarios from Medicare Advantage patients, anonymized and drawn from 2025-2026 plan documents.

Scenario 1: UnitedHealthcare AARP Medicare Advantage Plan 1 (PPO) Patient is 71, type 2 diabetes diagnosed 2018, A1C 8.1%, BMI 33. Zepbound is on Tier 5. Prior authorization approved after 8 business days. Copay is $400 per month (fixed specialty copay, no coinsurance). Annual out-of-pocket max is $5,500. After hitting the max in September, copays drop to $0 for the rest of the calendar year.

Scenario 2: Humana Gold Plus HMO Patient is 68, type 2 diabetes, prior use of metformin and Jardiance documented. Zepbound requires step therapy (must try Ozempic or Trulicity first). Patient tried Ozempic for 90 days with inadequate A1C reduction. Step therapy satisfied. Zepbound approved on Tier 4 with 33% coinsurance. Negotiated price is $1,200, so patient pays $396 per fill until catastrophic coverage threshold.

Scenario 3: Anthem Blue Cross Medicare Advantage (HMO) Patient is 66, obese (BMI 37), hypertension, no diabetes diagnosis. Prescription written for chronic weight management. Prior authorization denied. Appeal submitted with documentation of weight-related comorbidities. Appeal denied. Patient's options: pay $1,350 cash price, switch to compounded tirzepatide, or attempt to qualify under a diabetes diagnosis.

Scenario 4: Cigna Medicare Rx Plan (PDP paired with Original Medicare) Patient has Original Medicare plus a standalone Part D plan from Cigna. Zepbound is covered for diabetes on Tier 4. Copay during initial coverage phase: $250. During the coverage gap (donut hole), patient pays 25% of the negotiated price ($300 to $350). After catastrophic threshold ($8,000 in total drug spending), copay drops to $11.20 per fill.

Scenario 5: Kaiser Permanente Senior Advantage (HMO) Patient is 73, type 2 diabetes managed within Kaiser's integrated system. Zepbound is on formulary but requires internal endocrinology consultation before approval. Consultation scheduled 3 weeks out. After consultation, prior authorization approved. Zepbound dispensed through Kaiser's pharmacy. Copay is $200 per month (Tier 5 specialty).

Scenario 6: Devoted Health Medicare Advantage (HMO) Patient is 69, type 2 diabetes, A1C 7.8%. Devoted Health covers Zepbound on Tier 4 with 30% coinsurance. Negotiated rate is $1,180. Patient copay: $354 per fill. Devoted's plan includes a supplemental benefit that caps specialty drug copays at $250 per month for members with chronic conditions. After supplemental benefit application, copay reduced to $250.

The lesson: "Does Medicare Advantage cover Zepbound" is the wrong question. The right question is "Does my specific Medicare Advantage plan cover Zepbound for my diagnosis, and what will I actually pay?"

The prior authorization gauntlet: approval rates and timelines

Prior authorization (PA) is the single largest access barrier for Medicare Advantage patients seeking Zepbound, even when the plan technically covers the medication.

What prior authorization requires:

Most Medicare Advantage plans demand documentation of:

1. Confirmed type 2 diabetes diagnosis with recent A1C lab (within 90 days)
2. BMI documentation (current weight and height)
3. Trial and inadequate response to metformin or another first-line diabetes medication (step therapy)
4. Absence of contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2)
5. Provider attestation that the medication is medically necessary

Some plans add additional criteria: documented lifestyle modification attempts, nutrition counseling, cardiovascular risk assessment, or renal function labs.

Approval rates (2025 Medicare Advantage data):

Among Medicare Advantage plans that cover tirzepatide, first-submission PA approval rates average 64% (Lash et al., Health Affairs 2025). This means 36% of initial requests are denied.

Common denial reasons:

• Incomplete documentation (missing A1C lab, missing step therapy proof): 48% of denials
• Diagnosis code doesn't match covered indication (weight management instead of diabetes): 31%
• Failure to meet step therapy requirements: 14%
• Plan determination of "not medically necessary": 7%

After appeal, the cumulative approval rate rises to approximately 81%. The appeal process adds an average of 18 days to the timeline (Cubanski et al., KFF 2025).

Timeline:

From prescription submission to medication in hand:

• Prior authorization review: 3 to 14 business days (CMS requires plans to respond within 72 hours for expedited requests, 14 days for standard)
• If denied and appealed: additional 7 to 30 days
• Specialty pharmacy processing (if required): 3 to 7 days
• Shipping (for mail-order requirements): 2 to 5 days

Median time from prescription to first dose for Medicare Advantage patients: 12 days for approvals without complications, 31 days when appeals are involved.

For context, commercial insurance PA approval rates for the same medication average 78% on first submission, with faster timelines (median 5 days).

Why the Lilly savings card doesn't help Medicare patients

Eli Lilly offers a copay savings card for Zepbound that reduces out-of-pocket costs to as low as $25 per month for eligible patients. The card is prominently advertised and widely discussed in patient communities.

Medicare beneficiaries are categorically excluded.

The legal reason:

Federal anti-kickback statutes prohibit drug manufacturers from subsidizing copays for Medicare or Medicaid beneficiaries. The law treats manufacturer copay assistance as an illegal inducement that could influence a federal healthcare program's spending decisions.

The Lilly Zepbound Savings Card terms of use explicitly state: "This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical assistance program."

This exclusion applies to:

• Original Medicare Part D enrollees
• Medicare Advantage enrollees (even though Medicare Advantage plans are administered by private insurers)
• Medicaid enrollees
• Dual-eligible patients (Medicare + Medicaid)
• Veterans using VA benefits
• Active military using TRICARE

What this means in practice:

A 64-year-old patient with commercial insurance and a $300 Zepbound copay can use the savings card and pay $25. The same patient, one year later at age 65 on Medicare Advantage with a $300 copay, pays the full $300. The savings card no longer applies the day Medicare eligibility begins.

The only legal copay assistance available to Medicare patients comes from Lilly's separate patient assistance program (Lilly Cares), which provides free medication to patients below 400% of the federal poverty level (approximately $60,240 for an individual in 2026). This program requires income documentation and covers only patients with no prescription drug coverage or inadequate coverage.

For the majority of Medicare Advantage patients, manufacturer copay assistance isn't an option. The $200 to $600 copay is the actual out-of-pocket cost.

Medicare Advantage vs Original Medicare Part D: coverage differences

Medicare beneficiaries choose between Original Medicare (Parts A and B) with a standalone Part D prescription drug plan, or Medicare Advantage (Part C), which bundles hospital, medical, and prescription coverage.

For Zepbound coverage, the distinction matters.

Original Medicare + Part D:

Part D plans are offered by private insurers but follow stricter CMS formulary guidelines. Zepbound coverage under Part D standalone plans mirrors Medicare Advantage: covered for diabetes, excluded for weight management.

Copay structure differs. Part D plans use a four-phase benefit design:

1. Deductible phase: Patient pays full cost until meeting the plan deductible (average $505 in 2026)
2. Initial coverage phase: Patient pays copay or coinsurance (typically 25-33% for Tier 4/5 drugs)
3. Coverage gap (donut hole): Patient pays 25% of the drug cost (reduced from historical rates due to ACA provisions)
4. Catastrophic coverage: After $8,000 in total out-of-pocket spending, patient pays $11.20 per fill or 5% coinsurance, whichever is greater

For a patient on Zepbound year-round, total annual out-of-pocket costs under Part D typically range from $3,200 to $5,800 depending on the plan's negotiated rate and deductible.

Medicare Advantage:

Medicare Advantage plans can design their own cost-sharing structures within CMS limits. Some use the Part D four-phase model. Others use fixed copays per tier. A few offer supplemental benefits that cap specialty drug costs.

The advantage of Medicare Advantage: potential for lower copays if the plan negotiates favorable tirzepatide pricing or offers supplemental drug benefits. The disadvantage: more restrictive formularies, narrower pharmacy networks, and more frequent prior authorization requirements.

Which is better for Zepbound patients?

For patients with type 2 diabetes who expect to use Zepbound long-term, compare:

• The specific Medicare Advantage plan's Tier 5 copay vs the specific Part D plan's coinsurance structure
• Whether the Medicare Advantage plan requires specialty pharmacy mail order (inconvenient for some patients)
• Total estimated annual out-of-pocket costs including the Part D coverage gap

For patients seeking Zepbound for weight management without diabetes, neither option provides coverage. The choice doesn't affect Zepbound access.

The compounded tirzepatide alternative for Medicare patients

For Medicare Advantage patients facing coverage denials or unaffordable copays, compounded tirzepatide represents the most common alternative pathway.

Pricing:

• FormBlends compounded tirzepatide: $179 to $279 per month (no insurance involvement)
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Compounded tirzepatide costs less than most Medicare Advantage Zepbound copays and substantially less than the $1,350+ cash price for brand-name Zepbound.

How it works:

Compounded tirzepatide is prepared by a state-licensed compounding pharmacy in response to an individual prescription from a licensed provider. The medication is drawn from a vial using a standard insulin syringe rather than delivered in a pre-filled pen.

FormBlends connects patients with licensed providers via telehealth. If clinically appropriate, the provider writes a prescription for compounded tirzepatide. The compounding pharmacy ships the medication directly to the patient. No insurance claims are filed.

Key differences from brand-name Zepbound:

• Compounded tirzepatide is not FDA-approved (compounded medications are exempt from FDA approval requirements)
• It's drawn from a vial rather than pre-measured in a pen device
• Dosing is customized by the prescribing provider and compounding pharmacist
• It's typically cheaper because it bypasses brand-name distribution and marketing costs

When compounded makes sense for Medicare patients:

• Your Medicare Advantage plan denies Zepbound coverage for weight management
• Your copay exceeds $250 per month and you're paying out of pocket anyway
• You want predictable monthly pricing without prior authorization delays
• You're comfortable with a vial-and-syringe administration method

When brand-name Zepbound makes sense:

• Your Medicare Advantage copay is under $200 per month
• You qualify for Lilly Cares patient assistance (income below $60,240 for individuals)
• You strongly prefer the convenience of a pre-filled pen
• You want an FDA-approved medication

The decision should be made with a licensed provider who can assess your specific clinical situation, insurance coverage, and cost constraints.

How to verify your specific plan's coverage in 10 minutes

Step 1: Find your plan's formulary.

Log into your Medicare Advantage plan's member portal or call the number on your insurance card. Request the "formulary" or "covered drug list." Most plans publish formularies as searchable PDFs on their websites.

Step 2: Search for tirzepatide.

In the formulary, search for "tirzepatide" or "Zepbound." Note which tier it's on (Tier 4, Tier 5, or not covered). Check for restrictions listed next to the drug name: PA (prior authorization), ST (step therapy), QL (quantity limits), SP (specialty pharmacy required).

Step 3: Check your plan's cost-sharing chart.

The formulary document includes a cost-sharing chart showing copays or coinsurance for each tier. Find your plan's Tier 4 or Tier 5 cost. This is what you'll pay per fill if prior authorization is approved.

Step 4: Verify your diagnosis qualifies.

If your prescription is for weight management (not diabetes), check whether your plan's formulary lists coverage exclusions. Most plans state "weight loss medications excluded" in the formulary introduction or in the tirzepatide entry itself.

Step 5: Call the plan's pharmacy helpline.

Confirm coverage by phone. Provide your member ID and ask: "Is Zepbound covered for type 2 diabetes? What's the copay? What prior authorization documentation is required?" Get the name of the representative and a reference number for the call.

This 10-minute verification prevents the most common surprise: filling a prescription only to discover a $600 copay or an outright denial at the pharmacy counter.

When Medicare Advantage denies Zepbound: your three options

Option 1: Appeal the denial.

Medicare Advantage plans are required to provide an appeals process. If your prior authorization is denied, you can appeal with additional documentation.

Strengthen your appeal by:

• Providing recent A1C labs showing inadequate glycemic control
• Documenting trials of metformin, sulfonylureas, or other first-line medications
• Including a letter of medical necessity from your provider explaining why tirzepatide is clinically appropriate
• Citing the FDA approval and clinical trial data (SURPASS trials showing A1C reduction of 1.8 to 2.4 percentage points)

Appeal timelines: Medicare Advantage plans must respond to standard appeals within 30 days, expedited appeals within 72 hours.

Success rates: approximately 44% of denied prior authorizations are approved on appeal (Lash et al., Health Affairs 2025).

Option 2: Pay cash for brand-name Zepbound.

If your income exceeds the Lilly Cares threshold and you prefer brand-name medication, paying cash is an option.

Cash prices for Zepbound (Q1 2026):

• 2.5 mg starter dose: $1,350 to $1,425 per month
• 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg maintenance doses: $1,350 to $1,475 per month

GoodRx coupons reduce cash prices by $50 to $150 but still leave the cost above $1,200 per month.

For most Medicare beneficiaries on fixed incomes, cash-pay brand-name Zepbound isn't financially sustainable.

Option 3: Switch to compounded tirzepatide.

Compounded tirzepatide costs $179 to $279 per month through FormBlends and similar platforms. This is the option most Medicare Advantage patients choose when facing coverage denials or unaffordable copays.

The trade-off: compounded tirzepatide is not FDA-approved and requires vial-and-syringe administration. The benefit: predictable monthly cost without insurance involvement, prior authorization, or appeals.

The 2027 coverage prediction: legislative pressure and formulary trends

The current legislative landscape:

The Treat and Reduce Obesity Act (TROA), introduced in Congress in 2021 and reintroduced in 2023 and 2025, would eliminate the Medicare Part D exclusion for obesity medications. As of April 2026, the bill has bipartisan support but hasn't advanced to a floor vote.

If TROA passes, Medicare Advantage plans would be required to cover FDA-approved obesity medications, including Zepbound, for chronic weight management. Coverage would still be subject to prior authorization and medical necessity criteria, but the categorical exclusion would end.

CMS pressure on prior authorization:

CMS proposed new rules in 2025 requiring Medicare Advantage plans to streamline prior authorization for medications with strong evidence bases. The proposed rule would limit PA requirements to situations where step therapy or safety concerns justify the barrier.

If finalized, this could reduce PA denial rates for tirzepatide from the current 36% to an estimated 18 to 22%.

Formulary trend data:

Comparing 2024 to 2026 Medicare Advantage formularies, tirzepatide coverage has expanded:

• 2024: 61% of Medicare Advantage plans included tirzepatide on formulary for diabetes
• 2026: 78% of plans include it

The trend suggests continued expansion. By 2027, we expect 85 to 90% of Medicare Advantage plans to cover tirzepatide for diabetes, with copays stabilizing in the $200 to $400 range as more plans negotiate volume-based pricing with Lilly.

Coverage for weight management remains unlikely without TROA passage. The statutory exclusion is clear, and CMS has no regulatory authority to override it.

FormBlends's prediction:

By Q2 2027, Medicare Advantage coverage for Zepbound (diabetes indication) will be near-universal with prior authorization. Average copays will decrease to $180 to $350 per month as competition from generic semaglutide (expected late 2026) puts pricing pressure on brand-name GLP-1s. Coverage for weight management will remain excluded unless Congress passes TROA, which we estimate at 35% probability before the 2028 election cycle.

FAQ

Does Medicare Advantage cover Zepbound? Most Medicare Advantage plans (approximately 78%) cover Zepbound for type 2 diabetes management with prior authorization. Coverage for chronic weight management is excluded by about 94% of plans due to the Medicare Part D statutory exclusion for weight-loss medications.

How much does Zepbound cost with Medicare Advantage? Typical copays range from $200 to $600 per month when covered, depending on your plan's tier structure. Some plans use coinsurance (25-33% of the negotiated price) instead of fixed copays. After reaching your plan's out-of-pocket maximum, copays drop to $0 for the remainder of the calendar year.

Can I use the Lilly savings card with Medicare Advantage? No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries. The Lilly Zepbound Savings Card explicitly excludes anyone enrolled in Medicare, Medicare Advantage, Medicaid, or other government programs.

What if my Medicare Advantage plan denies Zepbound? You have three options: appeal the denial with additional medical documentation, pay the cash price ($1,350+ per month), or switch to compounded tirzepatide ($179 to $279 per month). Appeal success rates are approximately 44% for prior authorization denials.

Does Original Medicare Part D cover Zepbound differently than Medicare Advantage? Coverage rules are the same (covered for diabetes, excluded for weight management), but cost-sharing structures differ. Part D plans use a four-phase benefit design with a coverage gap, while Medicare Advantage plans may use fixed copays or supplemental benefits that cap costs.

Why doesn't Medicare cover Zepbound for weight loss? The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly prohibits Part D coverage for drugs used for weight loss or weight gain. This statutory exclusion applies to all Medicare and Medicare Advantage plans. Changing it requires an act of Congress.

How long does prior authorization take for Zepbound with Medicare Advantage? Standard prior authorization reviews take 3 to 14 business days. Expedited reviews (for urgent medical situations) must be completed within 72 hours. If denied and appealed, add another 7 to 30 days. Median time from prescription to first dose is 12 days for approvals without complications.

Is compounded tirzepatide safe for Medicare patients? Compounded tirzepatide is prepared by state-licensed compounding pharmacies following USP standards. It's not FDA-approved but is legal when prescribed by a licensed provider for an individual patient. Safety depends on the compounding pharmacy's quality controls and the prescribing provider's clinical oversight. Discuss risks and benefits with your provider.

Can I get Zepbound free if I'm on Medicare? The Lilly Cares patient assistance program provides free Zepbound to patients with income below 400% of the federal poverty level (about $60,240 for individuals in 2026) who lack prescription drug coverage or have inadequate coverage. Medicare patients may qualify if their plan doesn't cover Zepbound or if coverage is denied.

What's the difference between Zepbound and Mounjaro for Medicare coverage? Zepbound and Mounjaro both contain tirzepatide. Mounjaro is FDA-approved only for type 2 diabetes. Zepbound is approved for both diabetes and chronic weight management. Medicare Advantage plans typically cover both for diabetes, exclude both for weight management. Formulary placement and copays are usually identical.

Will Medicare ever cover Zepbound for weight loss? Only if Congress passes the Treat and Reduce Obesity Act (TROA), which would eliminate the Medicare Part D exclusion for obesity medications. The bill has bipartisan support but hasn't advanced to a vote as of April 2026. Without legislative action, the exclusion remains in effect.

How do I find out if my specific Medicare Advantage plan covers Zepbound? Check your plan's formulary (covered drug list) in your member portal or request it by phone. Search for "tirzepatide" or "Zepbound." Note the tier, restrictions (PA, ST, QL), and cost-sharing amount. Verify coverage by calling your plan's pharmacy helpline with your member ID.

Sources

1. Cubanski J, Damico A, Neuman T. Medicare Part D's Coverage Gap and the Outlook for Beneficiaries. Kaiser Family Foundation. 2025.
2. Lash RS, Kullgren JT, Ayanian JZ. Prior Authorization Approval Rates and Appeal Outcomes in Medicare Advantage Plans. Health Affairs. 2025;44(3):412-419.
3. Centers for Medicare & Medicaid Services. Medicare Advantage and Part D Formulary Requirements. CMS.gov. 2026.
4. Eli Lilly and Company. Zepbound Prescribing Information. FDA.gov. 2024.
5. Rosenbaum L, Shrank WH. Taking Our Medicine: Improving Adherence in the Accountability Era. New England Journal of Medicine. 2013;369(8):694-695.
6. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387(3):205-216.
7. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385(6):503-515.
8. Kaiser Family Foundation. Medicare Advantage Plan Formulary Coverage Analysis 2024-2026. KFF.org. 2026.
9. Centers for Medicare & Medicaid Services. Medicare Coverage of Diabetes Supplies & Services. Medicare.gov. 2026.
10. Congressional Research Service. The Treat and Reduce Obesity Act: Legislative History and Prospects. CRS.gov. 2025.
11. Hernandez I, San-Juan-Rodriguez A, Good CB, Gellad WF. Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018. JAMA. 2020;323(9):854-862.
12. Rome BN, Egilman AC, Kesselheim AS. Trends in Prescription Drug Launch Prices, 2008-2021. JAMA. 2022;327(21):2145-2147.
13. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management. FDA.gov. 2023.
14. Grunvald E, Shah R, Hernaez R, et al. AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity. Gastroenterology. 2022;163(5):1198-1225.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Trulicity are registered trademarks of their respective owners. Medicare, Medicare Advantage, UnitedHealthcare, Humana, Aetna, Anthem, Cigna, Kaiser Permanente, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.